Acceleron Pharma Inc. (NASDAQ:XLRN) – Equities research analysts at Leerink Swann issued their Q2 2017 earnings per share (EPS) estimates for shares of Acceleron Pharma in a report issued on Wednesday. Leerink Swann analyst G. Porges anticipates that the brokerage will post earnings of ($0.66) per share for the quarter. Leerink Swann has a “Buy” rating and a $50.00 price target on the stock. Leerink Swann also issued estimates for Acceleron Pharma’s Q3 2017 earnings at ($0.75) EPS, Q4 2017 earnings at ($0.81) EPS, FY2017 earnings at ($2.83) EPS and FY2018 earnings at ($2.33) EPS.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.02. The firm earned $3 million during the quarter, compared to the consensus estimate of $4.08 million. Acceleron Pharma had a negative return on equity of 30.75% and a negative net margin of 229.77%.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the propert of of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this story can be viewed at http://www.watchlistnews.com/q2-2017-earnings-forecast-for-acceleron-pharma-inc-issued-by-leerink-swann-xlrn/1061442.html.

Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday. Oppenheimer Holdings, Inc. started coverage on shares of Acceleron Pharma in a research report on Sunday, December 25th. They set a “buy” rating and a $44.00 price target for the company. Cann started coverage on shares of Acceleron Pharma in a research report on Monday, December 12th. They issued an “outperform” rating and a $44.00 target price for the company. Citigroup Inc. started coverage on shares of Acceleron Pharma in a research report on Thursday, September 29th. They issued a “neutral” rating and a $40.00 target price for the company. Finally, FBR & Co reaffirmed a “buy” rating on shares of Acceleron Pharma in a research report on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $45.82.

Acceleron Pharma (NASDAQ:XLRN) opened at 25.53 on Friday. The company’s market cap is $963.66 million. The stock has a 50 day moving average of $30.96 and a 200 day moving average of $32.32. Acceleron Pharma has a 12-month low of $22.67 and a 12-month high of $41.69.

In related news, Director Jean George sold 453,505 shares of Acceleron Pharma stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $38.39, for a total transaction of $17,410,056.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Kevin F. Mclaughlin sold 1,700 shares of Acceleron Pharma stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $27.45, for a total transaction of $46,665.00. Following the transaction, the chief financial officer now owns 72,200 shares in the company, valued at approximately $1,981,890. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the propert of of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this story can be viewed at http://www.watchlistnews.com/q2-2017-earnings-forecast-for-acceleron-pharma-inc-issued-by-leerink-swann-xlrn/1061442.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XLRN. Morgan Stanley boosted its position in Acceleron Pharma by 1,540.3% in the third quarter. Morgan Stanley now owns 811,749 shares of the biopharmaceutical company’s stock worth $29,378,000 after buying an additional 762,262 shares during the period. Laurion Capital Management LP purchased a new position in Acceleron Pharma during the third quarter worth $24,971,000. Pictet Asset Management Ltd. boosted its position in Acceleron Pharma by 744.9% in the second quarter. Pictet Asset Management Ltd. now owns 727,427 shares of the biopharmaceutical company’s stock worth $24,885,000 after buying an additional 641,327 shares during the period. Westfield Capital Management Co. LP purchased a new position in Acceleron Pharma during the second quarter worth $16,793,000. Finally, RA Capital Management LLC purchased a new position in Acceleron Pharma during the third quarter worth $11,529,000. Institutional investors own 82.07% of the company’s stock.

About Acceleron Pharma

Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.

5 Day Chart for NASDAQ:XLRN

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.